Vitamin E and Vitamin C Treatment Improves Fibrosis in Patients with Nonalcoholic Steatohepatitis

American Journal of Gastroenterology

Volumn 98, Issue 11, 2003, Pages 2485-2490

  Harrison, Stephen A ^a   Torgerson, Sigurd ^b   Hayashi, Paul ^b   Ward, John ^b   Schenker, Steven ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; GLYCOSYLATED HEMOGLOBIN; LIPID; LIVER ENZYME;

ADULT; ARTICLE; BODY MASS; CELL DEATH; CELL DEGENERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HISTOLOGY; HUMAN; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; LOW FAT DIET; MALE; NONALCOHOLIC FATTY LIVER; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; VITAMIN INTAKE; WEIGHT REDUCTION;

EID: 0344742265     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.08699.x     Document Type: Article

References (27)

1. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002;13:17-30.
2. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-9.
3. Lee RG. Nonalcoholic steatohepatitis: A study of 39 patients. Hum Pathol 1989;20:594-598.
4. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
5. Garcia-Ruiz C, Colell A, Morales A, et al. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-K: Studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol 1995;48:824-34.
6. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-53.
7. Robino G, Parola M, Marra F, et al. Interaction between 4-hydroxy-2,3-alkenals and the PDGF-β receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem 2000;275:40561-7.
8. Seki S, Kitada T, Yamada T, et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56-62.
9. Hasegawa T, Yonada M, Nakamura K, et al. Plasma transforming growth factor beta level and efficacy of alpha-tocopherol in patients with nonalcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther 2001;15:1667-72.
10. Chan AC. Partners in defense, vitamin E and vitamin C. Can J Pharmacol 1993;71:725-31.
11. Brunt EM, Janney CG, Bisceglie D, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
12. Harrison SA, Diehl AM. Fat and the liver-a molecular overview. Semin Gastrointest Dis 2002;13:3-16.
13. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45.
14. Kim WR, Poterucha JJ, Porayko MK, et al. Recurrance of nonalcoholic steatohepatitis following liver transplant. Transpl 1996;62:1802-5.
15. Willmer IR, Waters B, Patil SR. Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61.
16. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37:154-60.
17. Bugianesi E, Leone N, Vanni G, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-40.
18. Matteoni CA, Younossi ZM, Gramlich T. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
19. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000;136:734-8.
20. Phung N, Farrell G, Robertson G. Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities. Hepatology 2001;34:361A (abstract).
21. Parola M, Leonarduzzi G, Biasi F, et al. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 1992;16: 1014-21.
22. Anania FA. Leptin, liver, and obese mice-fibrosis in the fast lane. Hepatology 2002;36:246-8.
23. Czaja MJ, Weiner PR, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-B1 with hepatic fibrosis. J Cell Biol 1989;108:2477-82.
24. Eghbali-Fatourechi G, Sleck GC, Prakash YS, et al. Type I procollagen production and cell proliferation is mediated by transforming growth factor-B in a model of hepatic fibrosis. Endocrinology 1996;137:1894-903.
25. Parola M, Muraca R, Dianzani I, et al. Vitamin E dietary supplementation inhibits tissue growth factor beta-1 gene expression in the rat liver. FEBS Lett 1992;308:267-70.
26. Ueno T, Sagawara H, Sujaka K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
27. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.